Jilin Pharmaceutical fourth recombination failure abandoning drug from house

Jilin Pharmaceutical reorganization failed again. Yesterday, the company said it received the first and second largest shareholder notice, the real estate industry, the major assets reorganization fell through, to the SFC to apply for the withdrawal of application documents.　　The reason is that the state of the real estate industry macro-control, so that the reorganization of assets has not been the basis for implementation. Reorganization coincided with real estate regulation last April, Jilin Pharmaceutical released a reorganization bill.　　said that the existing assets, liabilities and related business as a whole sold to two shareholders Jilin Golden Spring Baoshan Pharmaceutical Group Co., Ltd., at the same time to the controlling shareholder of the radio and Television group's broadcasting and Real estate Development Group Co.　　The idea at the time was for the company to get out of its misery by selling all its assets and liabilities to two shareholders, and at the same time issuing shares to controlling shareholders in private. But the company's attempt to move to the industry has failed.　　Jilin Pharmaceutical director told reporters yesterday, coincides with the State property control, restructuring is not successful reasons is obvious, the company is planning a new reorganization. Many times the so-called reorganization of "sell shell reorganization", may just want to throw the shell again.　　"said Bing, a medical researcher at the state consulting. This reorganization, in the past 3 years, the Jilin Pharmaceutical "shell-selling Restructuring" plan has 4 times, but no result. July 2008, the company has also been brewing "discard medicine from potassium", proposed to issue 900 million shares to buy land, such as waterfront potash rights and the right to use.　　Finally, the company said that because of the mining warrants and project approval difficult to complete, terminated the agreement. In the past few years, Jilin pharmaceutical business situation has deteriorated.　　2007, 2008, 2009 the company attributable to the listed company shareholders of the net profit of 18.7889 million yuan, 3.3222 million yuan and-15.6486 million yuan. Last year, the company's performance was even worse, announced on January 26, the results of the announcement of the 2010 annual loss of 27 million yuan.　　The company has lost for two consecutive years, according to the relevant provisions, the company's stock will be implemented risk warning treatment (ie *st processing). According to the above announcement, Jilin Pharmaceutical 2010 losses, mainly from the main business. Responsible Editor: NF018